October 3, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced two poster presentations, including a late breaker, at the Heart Failure Society of America (HFSA) 2022 Annual Meeting, which is being held September 30 – October 3, in Washington DC. 

October 3, 2022 — A new ‘ECHO lab’ at Memorial Hospital West is benefiting patients that may have heart disease and the cardiac specialists that treat them. 

September 29, 2022 —  HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo credit card-sized device was issued by the United States Patent and Trademark Office. The innovation opens the pathway for a patient to record a set of signals using HeartBeam AIMIGo outside of a medical setting with a diagnostic synthesized 12-lead ECG immediately transmitted to a physician for review and diagnosis.

September 29, 2022 — Bloodstream levels of a protein fragment called endotrophin can be used to predict outcomes in patients with a common form of heart failure, according to a study co-led by researchers at the Perelman School of Medicine at the University of Pennsylvania. 

September 28, 2022 —  A University of Massachusetts Amherst nurse engineer is leading a team of researchers who are developing a wearable vest system designed to monitor heart failure patients in their home and detect when their condition is worsening.